Controversial laser heart procedures find little favour among US MCAC (Medicare coverage advisory committee) panel
This article was originally published in Clinica
There is too little evidence to judge the potential health benefits of a procedure that uses lasers to drill holes in the heart's myocardium following coronary artery bypass surgery, a panel of experts told Medicare last week.
You may also be interested in...
More details about the controversial ORBITA trial.
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.
Ionis will seek US and EU approvals to treat familial chylomicronemia syndrome in the first half of 2024. Phase III data in the larger severe hypertriglyceridemia indication are due in late 2024 or early 2025.